According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “
CRIS has been the subject of several other research reports. Robert W. Baird reaffirmed an outperform rating and issued a $7.00 price objective on shares of Curis in a report on Wednesday, September 7th. FBR & Co reiterated a buy rating on shares of Curis in a research report on Thursday, September 8th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock has an average rating of Buy and an average target price of $4.56.
Shares of Curis (NASDAQ:CRIS) opened at 2.43 on Monday. The company’s market cap is $314.62 million. Curis has a one year low of $1.25 and a one year high of $3.18. The company’s 50-day moving average price is $1.88 and its 200 day moving average price is $1.76.
Curis (NASDAQ:CRIS) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.09) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.09). Curis had a negative return on equity of 65.51% and a negative net margin of 526.72%. The company earned $1.70 million during the quarter, compared to analyst estimates of $2.05 million. During the same quarter in the previous year, the company posted ($0.06) earnings per share. Curis’s revenue was down 19.0% compared to the same quarter last year. On average, equities research analysts anticipate that Curis will post ($0.38) earnings per share for the current year.
In other Curis news, major shareholder Discovery Technologie Aurigene acquired 10,208,333 shares of the stock in a transaction dated Wednesday, September 7th. The shares were acquired at an average cost of $2.40 per share, for a total transaction of $24,499,999.20. Following the completion of the transaction, the insider now directly owns 27,328,464 shares of the company’s stock, valued at $65,588,313.60. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 6.09% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Barclays PLC increased its position in shares of Curis by 10,149.4% in the second quarter. Barclays PLC now owns 64,059 shares of the company’s stock valued at $100,000 after buying an additional 63,434 shares during the last quarter. Metropolitan Life Insurance Co. NY acquired a new position in shares of Curis during the second quarter valued at approximately $146,000. ProShare Advisors LLC increased its position in shares of Curis by 1.3% in the second quarter. ProShare Advisors LLC now owns 109,812 shares of the company’s stock valued at $171,000 after buying an additional 1,418 shares during the last quarter. Rhumbline Advisers increased its position in shares of Curis by 27.2% in the second quarter. Rhumbline Advisers now owns 138,986 shares of the company’s stock valued at $217,000 after buying an additional 29,751 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of Curis during the first quarter valued at approximately $248,000. Institutional investors and hedge funds own 52.36% of the company’s stock.
Curis Company Profile
Curis, Inc is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.